Cardiovascular effects of conventional sulfonylureas and glimepiride.
about
Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiologyGlimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channelsAre hypoglycaemia and other adverse effects similar among sulphonylureas?In-vivo and in-vitro models of type 2 diabetes in pharmaceutical drug discovery.Cardiovascular effects of sulphonylureas: role of K(ATP) channels.Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea.Does glycemic control reverse dispersion of ventricular repolarization in type 2 diabetes?Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning.A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetesGlimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus.Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report.The path to approval of new drugs for diabetes.Comparative Evaluation of Safety and Efficacy of Glimepiride and Sitagliptin in Combination with Metformin in Patients with Type 2 Diabetes Mellitus: Indian Multicentric Randomized Trial - START Study.Effects of insulin, glimepiride and combination therapy of insulin and metformin on blood sugar and lipid profile of NIDDM patients.The NEPI antidiabetes study (NANSY). 1: short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose.
P2860
Q24805922-C5B73CF3-2361-43AC-97F2-D9D36AACDBC2Q28363877-BEC1BA3B-1065-43F6-AE0B-83CB253C9229Q31122704-1D0F7A78-9D23-4423-A25C-FD19423B3382Q34163311-A4528C63-21AB-4AE0-94BC-F03DF18B6E17Q34163342-EC6F81B0-BE7C-4718-820E-7F7718E26BA7Q34523733-09312F69-AFF4-48FF-A838-C351F51DEE35Q34570576-518A0546-DCC0-4C52-9931-8457275361DCQ35607945-991D9A90-CA1B-4C04-A6AC-9631C1A21820Q36251583-78174D6D-075F-4DE6-9189-695A4ADD9913Q36288965-982DD756-BAE0-4FC7-8EEE-4E665015BE8AQ36536205-7D79863F-86B6-4603-B755-CB418A85DCCDQ36899187-E2827967-089E-44B0-BE25-8FC8FF667859Q37541529-860CDCC0-B094-4BD2-87EC-48E46A441624Q38080152-AC476C80-098E-40D3-96A5-F878C47D8F9DQ42278727-FC23DE4F-DC06-4B6E-B506-5E33DFFA83CFQ42753220-6656B67E-23D2-45FF-8562-0F627B339476Q43923317-36173300-C50C-4974-A9C8-5EA19C1D4634
P2860
Cardiovascular effects of conventional sulfonylureas and glimepiride.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Cardiovascular effects of conventional sulfonylureas and glimepiride.
@en
type
label
Cardiovascular effects of conventional sulfonylureas and glimepiride.
@en
prefLabel
Cardiovascular effects of conventional sulfonylureas and glimepiride.
@en
P2093
P356
P1476
Cardiovascular effects of conventional sulfonylureas and glimepiride.
@en
P2093
P304
P356
10.1055/S-2007-979841
P577
1996-09-01T00:00:00Z